Scholarlink

Background <p>In 2021, IDegLira was introduced in China as a treatment option for patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the long-term cost-utility of IDegLira compared to basal-bolus therapy and glucagon-like peptide-1 receptor agonist (GLP-1RA) added to basal insulin in patients with T2DM who remain uncontrolled on basal insulin in China.</p> Methods <p>The Swedish Institute for Health Economics (IHE) T2DM Cohort Model was employed to project health and cost outcomes over a 30-year time horizon. Baseline cohort characteristics were derived from the DUAL II China study. Treatment effects were derived from DUAL VII study and a pooled analysis. Costs were considered from a health system perspective in China and expressed in 2023 Chinese yuan (CNY). Health outcomes were measured in quality-adjusted life years (QALYs). Health state utilities were obtained from several published sources. Future costs and clinical outcomes were discounted at an annual rate of 5%.</p> Results <p>IDegLira was associated with an improvement of 0.810 QALYs and a cost reduction of CNY 91,217 compared to basal-bolus therapy. Similarly, compared to GLP-1RA added to basal insulin, IDegLira demonstrated a health gain of 0.011 QALYs and a cost reduction of CNY 23,815, establishing IDegLira as the dominant option. The sensitivity analyses indicated a 100% probability of IDegLira being cost-effective.</p> Conclusions <p>For T2DM patients who remain uncontrolled on basal insulin, IDegLira was projected to be dominant and could offer better value compared to both basal-bolus therapy and GLP-1RA added to basal insulin in the Chinese setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Junling Weng,
  • Dunming Xiao,
  • Yingyao Chen

摘要

Background

In 2021, IDegLira was introduced in China as a treatment option for patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the long-term cost-utility of IDegLira compared to basal-bolus therapy and glucagon-like peptide-1 receptor agonist (GLP-1RA) added to basal insulin in patients with T2DM who remain uncontrolled on basal insulin in China.

Methods

The Swedish Institute for Health Economics (IHE) T2DM Cohort Model was employed to project health and cost outcomes over a 30-year time horizon. Baseline cohort characteristics were derived from the DUAL II China study. Treatment effects were derived from DUAL VII study and a pooled analysis. Costs were considered from a health system perspective in China and expressed in 2023 Chinese yuan (CNY). Health outcomes were measured in quality-adjusted life years (QALYs). Health state utilities were obtained from several published sources. Future costs and clinical outcomes were discounted at an annual rate of 5%.

Results

IDegLira was associated with an improvement of 0.810 QALYs and a cost reduction of CNY 91,217 compared to basal-bolus therapy. Similarly, compared to GLP-1RA added to basal insulin, IDegLira demonstrated a health gain of 0.011 QALYs and a cost reduction of CNY 23,815, establishing IDegLira as the dominant option. The sensitivity analyses indicated a 100% probability of IDegLira being cost-effective.

Conclusions

For T2DM patients who remain uncontrolled on basal insulin, IDegLira was projected to be dominant and could offer better value compared to both basal-bolus therapy and GLP-1RA added to basal insulin in the Chinese setting.